{"classes":[{"categories":[{"measurements":[{"comment":"NA: Not estimable due to insufficient events observed","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"NA: Not estimable due to insufficient events observed","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"description":"Duration of MMR was defined as the time from the date of first documented MMR to the earliest date of loss of MMR, progression to Accelerated phase (AP) or Blast crisis (BC), or Chronic myeloid leukemia (CML)-related death.","dispersionType":"Full Range","groups":[{"description":"Participants randomized to asciminib 40mg BID","id":"OG000","title":"Asciminib"},{"description":"Participants randomized to bosutinib 500mg QD","id":"OG001","title":"Bosutinib"}],"paramType":"MEDIAN","populationDescription":"MMR responder set included participants who achieved MMR at any time on randomized treatment. FAS comprised of all randomized participants.","reportingStatus":"POSTED","timeFrame":"216 Weeks","title":"Duration of Major Molecular Response (MMR)","type":"SECONDARY","unitOfMeasure":"Weeks"}